Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 18/10/2019
SIETES contiene 92826 citas

 
 
 1 a 20 de 62 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Cummings SR, Lui LY, Eastell R, Allen IE. Association between drug treatments for patients with osteoporosis and overall mortality rates: a meta-analysis. JAMA Intern Med 2019:19 de agosto. [Ref.ID 103179]
2.Enlace a cita originalTiene citas relacionadas Cita con resumen
Cummings SR, Kiel DP, Black DM. Vitamin D supplementation and increased risk of falling. A cautionary tale of vitamin supplements retold. JAMA Intern Med 2016;176:febrero. [Ref.ID 100024]
3. Cita con resumen
Hue TF, Cummings SR, Cauley JA, Bauer DC, Ensrud KE, Barrett-Connor E, Black DM. Effect of bisphosphonate use on risk of postmenopausal breast cancer. Results from the randomized clinical trials of alendronate and zoledronic acid. JAMA Intern Med 2014;174:1550-7. [Ref.ID 97886]
4. Cita con resumen
Bauer DC, Schwartz A, Palermo L, Cauley J, Hochberg M, Santora A, Cummings SR, Black DM. Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy. The FLEX study. JAMA Intern Med 2014;174:1126-34. [Ref.ID 97573]
5.Tiene citas relacionadas Cita con resumen
Black DM, Bauer DC, Schwartz AV, Cummings SR, Rosen CJ. Continuing bisphosphonate treatment for osteoporosis - For whom and for how long?. N Engl J Med 2012;366:2051-3. [Ref.ID 93039]
6.Tiene citas relacionadas Cita con resumen
Jamal SA, Hamilton CJ, Eastell R, Cummings SR. Effect of nitroglycerin ointment on bone density and strength in postmenopausal women. A randomized trial. JAMA 2011;305:800-7. [Ref.ID 90244]
7.Tiene citas relacionadas
Cummings SR, Thompson J, Eastell R. Lasofoxifene for postmenopausal women with osteoporosis. The authors reply. N Engl J Med 2010;362:2228-9. [Ref.ID 88664]
8.Tiene citas relacionadas Cita con resumen
Cummings SR, Ensrud K, Delmas PD, LaCroix AZ, Vukicevic S, Reid DM, Goldstein S, Sriram U, Lee A, Thompson J, Armstrong RA, Thompson DD, Powles T, Zanchetta J, Kendler D, Neven P, Eastell R, for the PEARL Study Investigators. Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med 2010;362:686-96. [Ref.ID 87912]
9.Tiene citas relacionadas Cita con resumen
Ensrud KE, Lui L-Y, Taylor BC, Schousboe JT, Donaldson MG, Fink HA, Cauley JA, Hillier TA, Browner WS, Cummings SR, for the Study of Osteoporotic Fractures Research Group. A comparison of prediction models for fractures in older women. Is more better?. Arch Intern Med 2009;169:2087-94. [Ref.ID 87415]
10.Tiene citas relacionadas
Cummings SR, Siris E, Wang A. Denosumab, osteoporosis, and prevention of fractures. Dr. Cummings and colleagues reply. N Engl J Med 2009;361:2190-1. [Ref.ID 87211]
11. Cita con resumen
Christiansen CF, Christensen S, Mehnert F, Cummings SR, Chapurlat RD, Sorensen HT. Glucocorticoid use and risk of atrial fibrillation or flutter. A population-based, case-control study. Arch Intern Med 2009;169:1677-83. [Ref.ID 86956]
12.Tiene citas relacionadas Cita con resumen
Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C, FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;361:756-65. [Ref.ID 86411]
13.Tiene citas relacionadas
Wardlaw D, Cummings SR, Van Meirhaeghe J, Bastian L, Tillman JB, Ranstam J, Eastell R, Shabe P, Talmadge K, Boonen S. Efficacy and safety of balloon kyphoplasty compared with non-surgical care for vertebral compression fracture (FREE): a randomised controlled trial. Lancet 2009;373:1016-24. [Ref.ID 85508]
14.Tiene citas relacionadas
Cummings SR, Stathopoulous V. Tibolone in older postmenopausal women. The authors reply. N Engl J Med 2008;359:2173. [Ref.ID 84478]
15. Cita con resumen
Cauley JA, LaCroix AZ, Wu L, Horwitz M, Danielson ME, Bauer DC, Lee JS, Jackson RD, Robbins JA, Wu C, Stanczyk FZ, LeBoff MS, Wactawski-Wende J, Sarto G, Ockene J, Cummings SR. Serum 25-hydroxyvitamin D concentrations and risk for hip fractures. Ann Intern Med 2008;149:242-50. [Ref.ID 83812]
16.Tiene citas relacionadas Cita con resumen
Cummings SR, Ettinger B, Delmas PD, Kenemans P, Stathopoulos V, Verweij P, Mol-Arts M, Kloosterboer L, Mosca L, Christiansen C, Bilezikian J, Kerzberg EM, Johnson S, Zanchetta J, Grobbee DE, Seifert W, Eastell R, for the LIFT Trial Investigators. The effects of tibolone in older postmenopausal women. N Engl J Med 2008;359:697-708. [Ref.ID 83749]
17. Cita con resumen
Heckbert SR, Li G, Cummings SR, Smith NL, Psaty BM. Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med 2008;168:826-31. [Ref.ID 82770]
18.Tiene citas relacionadas Cita con resumen
Sorensen HT, Christensen S, Mehnert F, Pedersen L, Chapurlat RD, Cummings SR, Baron JA. Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. BMJ 2008;336:813-6. [Ref.ID 82655]
19.
Ensrud KE, Ewing SK, Taylor BC, Fink HA, Cawthon PM, Stone KL, Hillier TA, Cauley JA, Hochberg MC, Rodondi N, Tracy JK, Cummings SR, for the Study of Osteoporotic Fractures Research Group. Comparison of 2 frailty indexes for prediction of falls, disability, fractures, and death in older women. Arch Intern Med 2008;168:382-9. [Ref.ID 82311]
20.Tiene citas relacionadas
Black DM, Schwartz AV, Cummings SR, Cauley JA, Palermo L, for the FLEX Research Group. Use of alendronate after 5 years of treatment. In reply. JAMA 2007;297:1980-1. [Ref.ID 80066]
Seleccionar todas
 
 1 a 20 de 62 siguiente >>